Original ArticlesPharmacologic Reversal of Direct Oral AnticoagulantsFarina, Nicholas PharmD, BCCCP; Miller, James T. PharmD, BCCCPAuthor Information Michigan Medicine Department of Pharmacy, Ann Arbor. Correspondence: Nicholas Farina, PharmD, BCCCP, Trauma/Burn Critical Care, 1111 E. Catherine St Victor Vaughan Bldg Room 301, Ann Arbor, MI 48103 ([email protected]). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Critical Care Nursing Quarterly: April/June 2018 - Volume 41 - Issue 2 - p 121-128 doi: 10.1097/CNQ.0000000000000193 Buy Metrics Abstract Direct oral anticoagulants are becoming increasingly popular in outpatient use. These medications have lacked specific reversal agents. However, this is changing. The Federal Food and Drug Administration approved idarucizumab for reversal of dabigatran in 2016, and another agent, andexanet alfa, is currently in clinical trials for reversal of rivaroxaban and apixaban. This article examines the efficacy and safety of these emerging reversal agents, as well as other historical agents for reversal of direct oral anticoagulants. © 2018 Wolters Kluwer Health, Inc. All rights reserved.